Navigation Links
CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
Date:10/31/2007

COSTA MESA, Calif., Oct. 31 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that Henry T. Harbin, MD has been appointed to the Company's Board of Directors. A psychiatrist with over 30- years experience in the behavioral health field, Dr. Harbin has served as the CEO of two national behavioral health care companies and has held numerous senior positions in both the public and private mental health sectors.

Len Brandt, chairman and CEO of CNS Response, commented, "CNS Response is extremely fortunate to add Dr. Harbin's experience and acumen to our Board of Directors. I simply don't know anyone who has been more at the forefront of advancing behavioral healthcare management these past twenty-five years. Beyond that, Dr. Harbin is a creative force who has already influenced our thinking on initiatives to accelerate the impact that the objective guidance of rEEG(SM) can make for patients and payers alike."

Among his past accomplishments, Dr. Harbin served as Commissioner of the President's New Freedom Commission on Mental Health from 2002 to 2003, chairing the subcommittee for the Interface between Mental Health and General Medicine. In addition to his Federal government experience, Dr. Harbin also spent 10 years in the public mental health system in Maryland, serving as Director of the State Mental Health Authority for three of those years.

As the chairman, CEO and President of Magellan Health Services, the country's leading behavioral managed care organization, Dr. Harbin led a company with approximately 6,500 employees and revenues of $1.7 billion. During his tenure from 1998 to 2004, Magellan managed the mental health and substance abuse benefits of approximately 70 million Americans including persons who were insured by private employers, Medicaid and Medicare. Prior to Magellan, Dr. Harbin worked for Green Spring Health Services, Inc., one of the largest managed behavioral health organizations in the country. Dr. Harbin held several executive positions at the company, including five years as its president and CEO.

Among his achievements in research, Dr. Harbin was a principal investigator and project director for multiple studies at the University of Maryland's Institute of Psychiatry and Human Behavior, and has served as a reviewer for the American Journal of Psychiatry, Journal of Nervous and Mental Disease, and Hospital & Community Psychiatry. Dr. Harbin has also been published in over 10 peer-reviewed articles.

Dave Jones, Managing Partner of Sail Venture Capital and a member of the CNS Response Board of Directors, remarked, "The experience and enthusiasm of the people becoming associated with CNS Response, including Dr. Henry Harbin, our new President, George Carpenter, the new Chief Medical Officer, Daniel Hoffman, MD, and others joining Len, combined with the core team, allows this company to capitalize on its extraordinary vision and opportunity."

About CNS Response

CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(SM) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG(SM) to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contacts:

Investor Relations:

Sara Ephraim

(646) 536-7002

sephraim@theruthgroup.com

Media:

Janine McCargo / Jason Rando

(646) 536-7033 / 7025

jmccargo@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE CNS Response, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
4. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
5. Health Minister Wants Names of Uncooperative Hospital Consultants
6. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
7. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
8. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
9. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
10. Study casts doubt on keyboard ills
11. Who Board To Discuss Asian Tsunami Related Health Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... GA (PRWEB) , ... January 16, 2017 , ... ... to announce their recent partnership with an innovator in the wheelchair accessibility industry, ... to motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new ...
(Date:1/16/2017)... ... ... One thing common to all types of cancer is that it’s a ... money spent screening for and treating cancer in the United States is estimated to ... than in any other country that has an advanced healthcare system, sometimes spending as ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
(Date:1/15/2017)... ... 14, 2017 , ... Wondering where to go this Valentine's Day? Well, there ... for a romantic, lobster feast in the comfort of your own home. Lobster Gram ... dinners will be featured until February 15th, 2017. , Romantic Dinner one is ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and services ... Scale is now available on Apple as a fun, free emoji sticker pack for ... one of the ten color coded values on The Emoji Scale. , On ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... and PUNE, India , January ... by Allied Market Research, titled, "Vital Signs Monitoring Devices Market ... Forecast, 2014-2022", projects that the global vital signs monitoring devices ... expected to reach $5,491 million by 2022, growing at a ... America was the leading regional market in global ...
(Date:1/16/2017)... Oregon and PUNE, India , January 16, 2017 ... Research, titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry Forecast, ... is expected to reach $4,531 million by 2022, registering a CAGR of 6.42% ... for more than one-third share of the global volume in 2015. ... ...
(Date:1/16/2017)... 16, 2017  Dovetail Genomics today announced the commercial ... service, which yields chromosome-scale genome assemblies. The service is ... workshop on Jan. 17 at the Plant & Animal ... . "We are thrilled to be ... our Dovetail Hi-C offering," said Todd Dickinson , ...
Breaking Medicine Technology: